Trial Profile
Study of sofosbuvir/velpatasvir (SOF/VEL) ± ribavirin (RBV) in the treatment of Genotype 3 (GT3) chronic hepatitis C (CHC) patients
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 12 Dec 2018
Price :
$35
*
At a glance
- Drugs Sofosbuvir/velpatasvir (Primary) ; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- 12 Dec 2018 New trial record
- 13 Nov 2018 Results presented at The Liver Meeting 2018: 69th Annual Meeting of the American Association for the Study of Liver Diseases